Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach

Therapeutic options for patients with treatment-resistant epilepsy represent an important unmet need. Addressing this unmet need was the main factor driving the drug discovery program that led to the synthesis of padsevonil, a first-in-class antiepileptic drug candidate that interacts with two thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Muglia, Pierandrea, Hannestad, Jonas, Brandt, Christian, DeBruyn, Steven, Germani, Massimiliano, Lacroix, Brigitte, Majoie, Marian, Otoul, Christian, Sciberras, David, Steinhoff, Bernhard J, Van Laere, Koen, Van Paesschen, Wim, Webster, Elizabeth, Kaminski, Rafal M, Werhahn, Konrad J, Toledo, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677606/
https://www.ncbi.nlm.nih.gov/pubmed/33241213
http://dx.doi.org/10.1093/braincomms/fcaa183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677606/
https://www.ncbi.nlm.nih.gov/pubmed/33241213
http://dx.doi.org/10.1093/braincomms/fcaa183

Ejemplares similares